Value-Based Care in Myeloma

Value-Based Care in Myeloma

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Clinical Trials, Multiple Myeloma

Chicago, IL—The triplet regimen of pomalidomide (Pomalyst), bortezomib (Velcade), and low-dose dexamethasone (PVd) significantly extended progression-free survival (PFS) compared with the doublet of bortezomib plus dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma who had previously received lenalidomide [ Read More ]

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Immunotherapy, Multiple Myeloma

Chicago, IL—The second-generation chimeric antigen receptor (CAR) T-cell therapy bb2121, engineered to target B-cell maturation antigen (BCMA), a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial [ Read More ]

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

ASH 2017, Multiple Myeloma, Palliative Care

Atlanta, GA—The largest-ever analysis of palliative care trends has found the use of palliative care services to be sporadic at best among patients with hematologic malignancies. According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied. [ Read More ]

Stem-Cell Transplant in Multiple Myeloma Associated with Increased Healthcare Utilization and Costs

Chase Doyle

Leukemia, Multiple Myeloma

Atlanta, GA—A recent analysis of US administrative claims data showed that stem-cell transplantation (SCT) is associated with increased healthcare resource utilization and costs compared with matched controls. According to data presented at 2017 ASH, patients who underwent SCT had, on average, >$114,000 increase in healthcare costs compared with age-, sex-, and comorbidity-matched patients with multiple myeloma who did not undergo SCT. [ Read More ]

Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Multiple Myeloma

Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 30,280 new cases of multiple myeloma will be diagnosed in 2017, and 12,590 deaths will be attributed to the disease. In the past 20 years, mortality rates associated with multiple myeloma have declined. Novel therapies, as well as improvements in autologous hematopoietic stem-cell transplantation (HSCT) procedures and supportive care, have contributed to extended survival for patients with this malignancy. [ Read More ]

Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free Survival

Wayne Kuznar

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Drug Updates, Multiple Myeloma

Atlanta, GA—Single-agent daratum­umab (Darzalex) shows significant activity in smoldering multiple myeloma (SMM). The 12-month progression-free survival (PFS) rate with a long dosing schedule of daratumumab was 95%, and the median PFS was not yet reached in any of the 3 dosing schedules studied, announced Craig C. Hofmeister, MD, MPH, Associate Professor, Division of Hematology, the Ohio State University, Columbus, at ASH 2017. [ Read More ]

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Multiple Myeloma, Value-Based Care

Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications. [ Read More ]